Induction of Immune Tolerance to FIX Following Muscular AAV Gene Transfer is AAV-dose/FIX-level Dependent

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2009 Feb 26

PMID 19240690

Citations 12

Authors

Meagan E Kelly

Jiacai Zhuo

Arpita S Bharadwaj

Hengjun Chao

Affiliations

Soon will be listed here.

Abstract

Direct intramuscular injection (IM) of adeno-associated virus (AAV) has been proven a safe and potentially efficient procedure for gene therapy of many genetic diseases including hemophilia B. It is, however, contentious whether high antigen level induces tolerance or immunity to coagulation factor IX (FIX) following IM of AAV. We recently reported induction of FIX-specific immune tolerance by IM of AAV serotype one (AAV1) vector in mice. We hypothesize that the expression of high levels of FIX is critical to induction of FIX tolerance. In this study, we investigated the correlation among AAV dose, FIX expression, and tolerance induction. We observed that induction of immune tolerance or immunity to FIX was dependent on the dose of AAV1-human FIX (hFIX) given and the level of FIX antigen expressed in both normal and hemophilia mice. We then defined the minimum AAV1-hFIX dose and the lowest level of FIX needed for FIX tolerance. Different from hepatic AAV-hFIX gene transfer, we found that FIX tolerance induced by IM of AAV1 was not driven by regulatory T cells. These results provided further insight into the mechanism(s) of FIX tolerance, contributing to development of hemophilia gene therapy, and optimization of FIX tolerance induction protocols.

Citing Articles

Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.

Gernoux G, Gruntman A, Blackwood M, Zieger M, Flotte T, Mueller C Mol Ther. 2020; 28(3):747-757.

PMID: 31982038 PMC: 7054721. DOI: 10.1016/j.ymthe.2020.01.004.

Lessons learned from lung and liver in-vivo gene therapy: implications for the future.

van Haasteren J, Hyde S, Gill D Expert Opin Biol Ther. 2018; 18(9):959-972.

PMID: 30067117 PMC: 6134476. DOI: 10.1080/14712598.2018.1506761.

Liver transplant tolerance and its application to the clinic: can we exploit the high dose effect?.

Cunningham E, Sharland A, Bishop G Clin Dev Immunol. 2013; 2013:419692.

PMID: 24307909 PMC: 3836300. DOI: 10.1155/2013/419692.

Role of antigen-specific regulatory CD4+CD25+ T cells in tolerance induction after neonatal IP administration of AAV-hF.IX.

Shi Y, Falahati R, Zhang J, Flebbe-Rehwaldt L, Gaensler K Gene Ther. 2013; 20(10):987-96.

PMID: 23759700 PMC: 3795474. DOI: 10.1038/gt.2013.22.

Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer.

Steel J, Di Pasquale G, Ramlogan C, Patel V, Chiorini J, Morris J Mol Ther. 2013; 21(3):680-7.

PMID: 23295951 PMC: 3589150. DOI: 10.1038/mt.2012.260.

References

Cohn E, Zhuo J, Kelly M, Chao H . Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer. J Thromb Haemost. 2007; 5(6):1227-36. DOI: 10.1111/j.1538-7836.2007.02522.x. View

Fields P, Arruda V, Armstrong E, Chu K, Mingozzi F, Hagstrom J . Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther. 2001; 4(3):201-10. DOI: 10.1006/mthe.2001.0441. View

Akbar A, Vukmanovic-Stejic M, Taams L, Macallan D . The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat Rev Immunol. 2007; 7(3):231-7. DOI: 10.1038/nri2037. View

Lanzavecchia A, Sallusto F . Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol. 2002; 2(12):982-7. DOI: 10.1038/nri959. View

Apostolou I, von Boehmer H . In vivo instruction of suppressor commitment in naive T cells. J Exp Med. 2004; 199(10):1401-8. PMC: 2211808. DOI: 10.1084/jem.20040249. View

DiMichele D . Immune tolerance: critical issues of factor dose, purity and treatment complications. Haemophilia. 2006; 12 Suppl 6:81-5. DOI: 10.1111/j.1365-2516.2006.01376.x. View

Manno C, Chew A, Hutchison S, Larson P, Herzog R, Arruda V . AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003; 101(8):2963-72. DOI: 10.1182/blood-2002-10-3296. View

Brown B, Lillicrap D . Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. Blood. 2002; 100(4):1133-40. DOI: 10.1182/blood-2001-11-0067. View

Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog R . Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther. 2005; 12(19):1453-64. DOI: 10.1038/sj.gt.3302539. View

10.

Ge Y, Powell S, Van Roey M, McArthur J . Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood. 2001; 97(12):3733-7. DOI: 10.1182/blood.v97.12.3733. View

11.

Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo M, Naldini L . Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood. 2004; 103(10):3700-9. DOI: 10.1182/blood-2003-09-3217. View

12.

Mitchison N . INDUCTION OF IMMUNOLOGICAL PARALYSIS IN TWO ZONES OF DOSAGE. Proc R Soc Lond B Biol Sci. 1964; 161:275-92. DOI: 10.1098/rspb.1964.0093. View

13.

Chao H, Walsh C . AAV vectors for hemophilia B gene therapy. Mt Sinai J Med. 2004; 71(5):305-13. View

14.

Mingozzi F, Liu Y, Dobrzynski E, Kaufhold A, Liu J, Wang Y . Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest. 2003; 111(9):1347-56. PMC: 154443. DOI: 10.1172/JCI16887. View

15.

Chao H, Monahan P, Liu Y, Samulski R, Walsh C . Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther. 2001; 4(3):217-22. DOI: 10.1006/mthe.2001.0449. View

16.

Cerullo V, McCormack W, Seiler M, Mane V, Cela R, Clarke C . Antigen-specific tolerance of human alpha1-antitrypsin induced by helper-dependent adenovirus. Hum Gene Ther. 2007; 18(12):1215-24. DOI: 10.1089/hum.2006.036. View

17.

Monahan P, Samulski R, Tazelaar J, Xiao X, Nichols T, Bellinger D . Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther. 1998; 5(1):40-9. DOI: 10.1038/sj.gt.3300548. View

18.

Herzog R, Fields P, Arruda V, Brubaker J, Armstrong E, McClintock D . Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther. 2002; 13(11):1281-91. DOI: 10.1089/104303402760128513. View

19.

Gao G, Alvira M, Wang L, Calcedo R, Johnston J, Wilson J . Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002; 99(18):11854-9. PMC: 129358. DOI: 10.1073/pnas.182412299. View

20.

Green D, Droin N, Pinkoski M . Activation-induced cell death in T cells. Immunol Rev. 2003; 193:70-81. DOI: 10.1034/j.1600-065x.2003.00051.x. View